presentation on a disease

Disease Presentations

Home Collections Medical Diseases

Free Diseases Presentation Templates

Elevate your health education and disease awareness campaigns with our free diseases powerpoint templates and google slides. these professionally designed templates with editable layouts and engaging visuals are perfect for enhancing understanding of disease symptoms, causes, and prevention. download today and empower your health education efforts.

We're here to help you!

What are disease powerpoint templates.

These templates are perfectly made with creative illustrations and infographics to help you make powerful presentations about various diseases, symptoms, preventions, treatments, etc.

Where can we use these Disease PPT Slides?

We can use these slides in hospitals, healthcare centers, medical colleges, schools, etc.

How can I make Disease PPT Slides in a presentation?

We can easily make creative presentations using pre-made slides. Do visit our YouTube tutorial videos, and tips and tricks pages to learn how to make these slides in a presentation.

Who can use Disease PowerPoint Templates?

Medical professionals, students, educators, and lab technicians can use these templates.

Why do we need Disease PowerPoint Slides?

These slides are the best choice to talk about different types of diseases, their prevention and treatment methods, and more. These slides will help you give a clear visual cue to your audience about the topics presented.

Where can I find Disease PPT Templates for free?

We can find a cluster of free templates at Slide Egg, one of the great sites for pre-made slides.

8th Grade Health: Disease/Condition/Disorder Project: Health Fair Presentation

• Topic Selection
• Print Sources
• Online Sources
• Bibliography
• Health Fair Presentation

Health Fair Requirements

Health Fair Presentation Requirements

Your presentation must include:

• Disease name, your name, class meeting days, date of presentation
• Introduction – Why you chose this disease, interesting facts about the disease, statistics
• Description – What is this disease, affected body parts
• Signs/Symptoms – Signs: observable, objective. Symptoms: what you feel, subjective. Minimum of 5
• Causes/Transmission – Risk factors, communicable/non-communicable
• Treatment/Prevention – Of disease, of symptoms, reduction of risk factors, how not to get this disease
• History – Some suggestions: Draw a timeline, list important dates, look for when it was discovered, important breakthroughs
• Interesting facts – Celebrities suffering from disease/condition, different parts of country where disease/condition is more prominent, etc.

*Remember – This is the part of the project where you can show your creativity. Use pictures, graphs, charts, diagrams, etc. to explain your disease/condition.

Audience Questions:

When you are going around to the different presenters, you must think of 2 thoughtful audience questions. You will write down the following on your Audience Questions Sheet. This sheet will be collected at the end of class.

Requirements for Audience Questions Sheet:

  Name and topic of presenter

      Question # 1 about disease/condition

           Answer that presenter gave about your question

      Question # 2 about disease/condition

Tri-Fold (Poster or Brochure)

Your health brochure can be completed in one of two ways:

• Using a computer program, such as Microsoft Publisher
• By hand, using heavy-duty construction paper

Your health brochure should include a cover, 4 sections of information, and the back.  Each section should have both written information, pictures, photos or clip art that correspond to the text.  See the attached document for details on how to arranged the brochure.

You may choose to leave an informative poster with the students after you have presented information about the disease/condition/disorder you choose.  A poster is a wonderful choice, since it can be hung in the hallway for the students to review as they walk to class.

Your informative poster must adhere to the following guidelines:

• Be presented on a larger size poster board (greater than 8x11 printed paper) or a tri-fold poster board.
• Name of the disease/condition/disorder researched must be highly visible
• Name of student and class period must be written in bottom right corner of poster
• Include the written information outlined in the research organizer
• Include pictures, photos or clip art that correspond to the text
• Information should either be typed and pasted onto poster or extremely neatly written in pen on poster
• Pencil marks should not be visible
• PowerPoint or Prezi

Your PowerPoint presentation should be used as a tool to guide you through your presentation to the 8 th grade health classes.  You must also provide a printed copy of the slides for the teacher.

Your slideshow must include at least 10 slides, but not exceed 15 slides.  Slides must include both written information and pictures, photos or clipart that corresponds to the text.

Use the attached guide to help you layout your slides.

Written Report

You may choose to leave a 2-3 page typed report with the students after you present your information to them.  Your report must include all of the information outlined on your notes pages.

Your report must adhere to the following guidelines:

• 2-3 pages in length (excluding cover page and bibliography)
• Typed in Microsoft Word
• Formatted with Arial font in size 12
• Double-spaced

Note: All reports must be written using the words of the student.  Plagiarism is a serious offense and is very easy for a teacher to catch.

See the attached document for details on what should be included on each page.

• << Previous: Bibliography
• Last Updated: Jan 27, 2016 2:09 PM
• URL: https://tesd.libguides.com/healthfair

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings

Preview improvements coming to the PMC website in October 2024. Learn More or Try it out now .

• Advanced Search
• Journal List
• Elsevier - PMC COVID-19 Collection

Pathology: The Clinical Description of Human Disease

This chapter discusses the fundamental concepts, terminology, and practice of pathology as the discipline dedicated to the understanding of causes, mechanisms, and effects of diseases. It describes some key terms, definitions, and concepts, presents historical human approaches to diseases, and provides an overview of current diagnostic practice and a vision for new interface with applied molecular biology. Pathology refers to the specialty of medical science concerned with the cause, development, structural/functional changes, and natural history associated with diseases. Disease refers to a definable deviation from a normal phenotype (observable characteristics due to genome and environment), evident via patient complaints (symptoms), and/or the measurements of a careful observer (signs). The cause of the disease is referred to as its etiology. One disease entity can have more than one etiology, and one etiology can lead to more than one disease. Each disease entity develops through a series of mechanistic chemical and cellular steps. This stepwise process of disease development is referred to as its pathogenesis. Pathogenesis can refer to the changes in the structure or function of an organism at the gross/clinical level and the stepwise molecular abnormalities leading to changes in cellular and tissue function. The presentation of a disease to a clinician is in the form of a human patient with variably specific complaints (symptoms), to which the examining physicians can add diagnostic sensitivity and specificity by making observations (screening for signs of diseases).

“…Future discoveries will not likely be made by morphologists ignorant of molecular biologic findings, or by biologists unaware or scornful of morphologic data, but by those willing and capable of integrating them through a team approach….” Rosai [ 1 ]

INTRODUCTION

This chapter will discuss the fundamental concepts, terminology, and practice of pathology as the discipline dedicated to the understanding of causes, mechanisms, and effects of diseases. A section on key terms, definitions, and concepts is followed by sections on historical human approaches to diseases, an overview of current diagnostic practice, and a vision for new interface with applied molecular biology.

TERMS, DEFINITIONS, AND CONCEPTS

Pathology (from the Greek word pathología , meaning the study of suffering) refers to the specialty of medical science concerned with the cause, development, structural/functional changes, and natural history associated with diseases. Disease refers to a definable deviation from a normal phenotype (observable characteristics due to genome and environment), evident via patient complaints (symptoms), and/or the measurements of a careful observer (signs). The cause of the disease is referred to as its etiology (from the Greek word meaning the study of cause). One disease entity can have more than one etiology, and one etiology can lead to more than one disease. Each disease entity develops through a series of mechanistic chemical and cellular steps. This stepwise process of disease development is referred to as its pathogenesis (from the Greek word meaning generation of suffering). Pathogenesis can refer to the changes in the structure or function of an organism at the gross/clinical level, and it can refer to the stepwise molecular abnormalities leading to changes in cellular and tissue function.

The presentation of a disease to a clinician is in the form of a human patient with variably specific complaints (symptoms), to which the examining physicians can add diagnostic sensitivity and specificity by making observations (screening for signs of diseases). These phenotypic (measurable characteristic) abnormalities reflect the interaction of the genotype (cytogenetic and nucleic acid sequence/expression) of the patient and his/her environment. Patient workup uses present illness history with reference to past medical history, review of other organ systems for other abnormalities, review of family history, physical examination, radiographic studies, clinical laboratory studies (for example, peripheral blood or CSF specimens), and anatomic pathology laboratory studies (for example, tissue biopsy or pleural fluid cytology specimens). As you will see from other chapters in this book, the ability to rapidly and inexpensively screen for chromosomal translocations, copy number variation, genetic variation, and abundance of mRNA and miRNA is adding substantial molecular correlative information to the workup of diseases.

The differential diagnosis represents the set of possible diagnoses that could account for symptoms and signs associated with the condition of the patient. The conclusion of the workup generally results in a specific diagnosis which meets a set of diagnostic criteria, and which explains the patient's symptoms and phenotypic abnormalities. Obviously, arrival at the correct diagnosis is a function of the examining physician and pathologist (fund of knowledge, experience, alertness), the prevalence of the disease in question in the particular patient (age, race, sex, site), and the sensitivity/specificity of the screening tests used (physical exam, vital signs, blood solutes, tissue stains, genetic assays). The pathologic diagnosis represents the best estimate currently possible of the disease entity affecting the patient, and is the basis for downstream follow-up and treatment decisions. The diagnosis implies a natural history (course of disease, including chronicity, functional impairment, survival) that most patients with this disease are expected to follow. Be aware that not all patients with a given disease will naturally follow the same disease course, so differences in patient outcome do not necessarily correspond to incorrect diagnosis. Variables that independently correlate with clinical outcome differences are called independent prognostic variables, and are routinely assessed in an effort to predict the natural history of the disease in the patient. It is also important to note that medical therapies for specific diseases do not always work. Variables that independently correlate with (predict) responses to therapy are called independent predictive variables.

Diagnosis of a disease and development of an effective therapy for that disease do not require knowledge of the underlying etiology or pathogenesis. For example, Wegener's granulomatosis was understood by morphology and outcomes to be a lethal disease without treatment, yet responsive to cyclophosphamide and corticosteroids, before it was found to be an autoimmune disease targeting neutrophil cytoplasmic protein PR3 ( Figure 11.1 ). However, understanding the molecular and cellular pathogenesis of a disease allows development of screening methods to determine risk for clinically unaffected individuals, as well as mechanistic approaches to specific therapy.

Wegener's granulomatosis of the lung . (A) H&E of Wegener's granulomatosis of lung. Necrosis, granulomatous inflammation, and vasculitis are identified. (B) Elastin stain of Wegener's granulomatosis of lung. Elastica disruption of the arterial wall supports a diagnosis of vasculitis.

The pathologist is that physician or clinical scientist who specializes in the art and science of medical risk estimation and disease diagnosis, using observations at the clinical, gross, body fluid, light microscopic, immunophenotypic, ultrastructural, cytogenetic, and molecular levels. Clearly, the pathologist has a duty to master any new concepts, factual knowledge, and technology that can aid in the estimation of risk for unaffected individuals, the statement of accurate and timely diagnosis, accurate prognosis, and accurate prediction of response to therapy for affected individuals.

A BRIEF HISTORY OF APPROACHES TO DISEASE

The ability of H. sapiens to adapt and thrive has been due in part to the ability of humans to remember the past, respect tradition, recognize the value of new observations, develop tools/symbols, manipulate the environment, anticipate the future, and role-specialize in a social structure. The history of human understanding of diseases has progressed at variable rates, depending on the good and bad aspects of these human characteristics.

Concepts and Practices Before the Scientific Revolution

Our understanding of ancient attitudes toward diseases is limited by the historical written record. Thus, the start point for written medical history corresponds to around 1700 BC for Mesopotamian rules in the code of Hammurabi, and around 1550 BC for the analogous Egyptian rules in the Ebers papyrus. By definition, these philosophers, theologians, and physicians had access and assets to allow a written record, and materials and storage sufficient for the written records to survive. The Mesopotamian records indicate a deity-driven and demon-driven theory and empirical practice by recognized professional physicians. In this context, the prevailing thought was that “Disease was caused by spirit invasion, sorcery, malice, or the breaking of taboos; sickness was both judgment and punishment” [ 2 ].

The Greek medical community evolved a theory of disease related to natural causes and effects, with less emphasis on deity-driven theory. The Hippocratic Corpus includes “On the Sacred Disease” (circa 400 BC), which rejected a divine origin for diseases, and postulated a natural rather than supernatural basis for disease etiology (“…nowise more divine nor more sacred than other diseases, but has a natural cause … like other affections.”). Aristotle (384–322 BC) wrote broadly on topics including logic, biology, physics, metaphysics, and psychology. To Aristotle, observations led to a description of causes, or first principles, which in turn could be used logically in syllogisms to predict future observations. We would agree with these basic notions of induction and deduction. However, there was a different background philosophical construct regarding the nature of matter and causality (four elements, four humors, and four causes, including a final or teleologic purpose). We would recognize Aristotle's “efficient” cause of a disease as its etiology. Alexander the Great's conquest of Egypt in the 4th century BC led to Greek (Ptolemaic) leadership of Egypt from 305 BC to 30 BC, with development of the Alexandrian library and University. Faculty such as Euclid developed geometric models of vision ( Optica ), and Herophilus described human anatomy by direct dissection and observation (Greek medicine apparently allowed dissection in Alexandria, including vivisection of the condemned). During the Roman imperial era, Galen (129–207 AD) used dissection and observation of other animals such as the macaque (human dissection was illegal) to extrapolate to human anatomy and physiology. Like Aristotle's approach, Galen's approach to patients, diseases, and treatments was guided by philosophical constructs of four humors (blood, phlegm, yellow bile, and black bile) and the resulting temperaments (buoyant, sluggish, quick-tempered, and melancholic) due to humoral imbalances. It is thought that many of Galen's texts were destroyed with the Alexandrian library before the 7th century AD, but a subset was preserved and translated by Middle Eastern scholars. These ancient classic texts were then retranslated into Latin and Greek when printing houses developed in the 15th century (for instance, Hippocrates' De Natura Hominis , circa 1480 AD, and Galen's Therapeutica , circa 1500 AD).

The historical picture of the Greco-Roman understanding of disease is one of empirical approaches to diseases based on inaccurate understanding of anatomy, physiology, and organ/cellular pathology. Greek medicine became less superstitious and more natural cause-and-effect oriented, yet philosophy still trumped direct observation, such that evidence was constrained to fit the classic philosophical constructs. Some of the concepts sound familiar; for example, normal represents equilibrium and disease represents disequilibrium. However, we would differ on what variables are in disequilibrium (the historical humors, numbers, and opposites versus contemporary chemical and kinetic equilibria).

Following the collapse of the Western Roman Empire in 476 AD, the classic texts of Aristotle, Hippocrates, and Galen were protected, translated, and built upon in the Byzantine and Arab societies of the near East, and in Spain during the Muslim/Moorish period through the 11th century. During these middle ages for Western Europe outside Spain, there was apparently a retreat to pre-Hellenistic beliefs in supernatural forces that intervened in human affairs, with protecting saints and relics for disease prevention and therapy. Centers of medical learning following the Spanish Muslim model developed in Montpellier, France, and in Salerno, Italy, beginning in the 11th century.

The Scientific Revolution

Aristotle's concept of induction from particulars to general first principles, then use of syllogistic logic to predict particulars, evolved into the scientific method during the Renaissance. Ibn Alhazen's (al-Haitham's) work on the physics of optics in the 11th century challenged Euclid's concepts of vision from the Alexandrian era. (Euclid thought that the eye generated the image, rather than light reflected from the object being received by the eye). In the 13th century, Roger Bacon reinforced this use of observation, hypothesis, and experimentation. The printing press (Gutenberg, 1440 AD) allowed document standardization and reproduction, such that multiple parallel university and city libraries could afford to have similar collections of critical texts, facilitating scholarly publications in journals. Access to publications in libraries and universities led to a system of review, demonstration, discussion, and consensus regarding new scientific findings.

The concept of the body as an elegant machine was captured not only by 15th and 16th centuries Renaissance artists like da Vinci and Michelangelo, but also by anatomists and pathologists interested in the structure/function of health and disease. The ancient models of Aristotle and Galen had become sacrosanct, and newer, evidence-based models were considered heretical to some degree. So it was somewhat revolutionary when Vesalius dissected corpses, compared them with Galenic descriptions, and published De humani corporis fabrica libri septem (1543 AD; “Seven Books on the Structure of the Human Body”; the Fabrica ), challenging and correcting 16th century understanding of normal human anatomy. Vesalius's successors (Colombo, Fallopius, and Eustachius) further improved the accuracy of human anatomic detail. Thus, correction of Galen's anatomical inaccuracies (including the rete mirabilis at the base of the brain, the five lobed liver, and curved humerus) required at least 13 centuries for challenge, scientific disproof, and eventual medical community acceptance.

The Scientific Revolution describes the progressive change in attitude of scientists and physicians toward understanding of the natural world, health, and disease. This revolution began circa 1543 AD, when Copernicus published arguments for a heliocentric universe and Vesalius published the Fabrica series on human anatomy. By the 17th century, Galileo, Kepler, Newton, Harvey, and others had used this observation-based, matter-based, and mathematical law-based perspective to develop a scientific approach similar to our own modern approach of testing hypotheses with experimental data and statistics. In human biology, the investigation of structure led to studies of function, initially of human cardiovascular physiology, for example, Harvey's Anatomical Exercise Concerning the Motion of the Heart and Blood in Animals (1628). Whereas Galen conceived of parallel but unconnected arteries and veins, with continuous blood production in the liver and continuous blood consumption in the periphery, Harvey demonstrated that blood was pumped by the heart through arteries, through tissue capillaries, to veins, and then back to the heart in a circle (circulation). Correction of these and other Galenic physiological inaccuracies (such as nasal secretions representing the filtrate of cerebral ventricle fluid) thus required at least 14 centuries before challenge, scientific disproof, and eventual medical community acceptance.

The scientific method facilitates empirical, rational, and skeptical approaches to observational data, and minimizes human dependence on non-evidence-based traditional models. In spite of the scientific method, physicians are still human, and the medical community still shows an inertial reluctance to adapt to new information when it disrupts traditional paradigms. Recent examples would include reluctance to accept an etiologic role for the H. pylori bacterium in peptic ulcer disease [ 3 ], and reluctance to offer less than radical mastectomy for primary breast carcinoma.

Discovery of the Microscopic World

Before the use of lenses to magnify objects, it was physically impossible to make observations on objects smaller than the resolving limit of the human eye (about 0.1–0.25 mm). Thus, prokaryotic and eukaryotic cells, tissue architecture, and comparisons of normal and disease microanatomy were philosophical speculation until description of the mathematics of optics and lens design. In a real sense, optical technology was rate-limiting for the development of the fields of tissue anatomy, cellular biology, and microbiology. Concepts of optics were written as early as 300 BC in Alexandria ( Optica , Euclid). Clear glass (crystallo) was developed in Venice in the 15th century. A compound microscope was invented by Janssen in 1590 AD. Microanatomy and structural terminology was begun by Malpighi (1661 AD), who examined capillaries in frog lung, trachea tubes for airflow in silkworms, and stomata in plant leaves. Robert Hooke used a compound microscope to describe common objects in Micrographia (1665 AD). Antony Van Leeuwenhoek used self-made simple magnifying lenses to count the threads in cloth in a Dutch dry-goods store, then later published descriptions of bacteria (termed animalcules ), yeast, and algae, beginning in 1673 AD. Yet the relevance of these observations in microanatomy and microbiology to human diseases required changes in conceptual understanding of the etiology and pathogenesis of diseases. For example, it was 200 years after Van Leeuwenhoek that the common bacterium Streptococcus was recognized as the etiologic agent of puerperal fever in post-partum women.

Critical Developments During the 19th Century

Cellular pathology, germ theory, and infectious etiologic agents.

The relevance of microanatomy and microbiology to human disease required expansion of conceptual understanding to include morphologic changes in diseased cells and tissues, as well as recognition of an etiologic role for microorganisms. Rokitansky's gross correlates with clinical disease ( A Manual of Pathological Anatomy , 1846, discussed in [ 4 ]), Paget's surgical perspective on gross pathology [ 5 ], and Virchow's morphologic correlates with clinical disease [ 6 ] were critical to the development of clinico-pathologic correlation, and served to create a role for pathologists to specialize in autopsy and tissue diagnosis. Virchow's description of necrotizing granulomatous inflammation, the morphologic correlate of infections caused by mycobacteria such as TB and leprosy, preceded the discovery of the etiologic agents years later by Hansen ( M. leprae , 1873 [ 7 ]) and Koch ( M. tuberculosis , 1882 [ 8 ]), reviewed in [ 9 ].

The causal relationship between microorganisms and clinical disease required scientific demonstration and logical proof before medical community acceptance. For example, it took two centuries for the common bacterium Streptococcus pyogenes to be recognized as the etiologic agent of puerperal fever in post-partum women. Identification of this cause-and-effect relationship required an initial recognition of unusual clinical outcomes (clusters of post-partum deaths), then correlation of puerperal fever clusters with obstetrician habits [ 10 , 11 ], then Semmelweiss's experimental demonstration in 1847 that hand-washing reduced the incidence of puerperal fever [ 12 ], then the demonstration that particular bacteria ( Streptococci ) are regularly associated with the clinical disease (Koch, circa 1870), and finally by culture of the organism from the blood of patients with the disease (Pasteur, 1879).

During the 19th century, critical causal associations between microorganisms and infectious diseases were proven and accepted. Technical improvements in microscopes (Abbe condenser, apochromatic lenses, oil immersion lenses), the development of culture media, and the development of histochemical stains no doubt made it possible for Koch to identify M. tuberculosis in 1882 [ 8 ]. To be emphasized is the process of recognition, first of all of the variables associated with the clinical disease, then the scientific demonstration of a causal relationship between one or more of these variables with the clinical disease. This latter step was enunciated as Koch's postulates (1890): (i) the bacteria must be present in every case of the disease, (ii) the bacteria must be isolated from a diseased individual and grown in pure culture, (iii) the specific disease must be reproduced when a pure culture is inoculated into a healthy susceptible host, and (iv) the same bacteria must be recoverable from the experimentally infected host.

Organic Chemistry

Prior to 1828, organic (carbon-containing) compounds were thought to derive from living organisms, and it was thought that they could never be synthesized from nonliving (inorganic) material. This concept (termed vitalism) was disproven by the in vitro synthesis of urea by F. Wohler in 1828 [ 13 ]. Work from this era initiated the field of organic chemistry. Predictable rules for in vitro and in vivo organic reactions, structural theory, modeling, separation technologies, and accurate measurement subsequently allowed the chemical description of natural products, and the chemical synthesis of both natural products and synthetic compounds. In addition to setting the stage for a systematic understanding of cellular biochemistry and physiology, organic chemistry set the stage for laboratory synthesis of natural products, such as dyes, vitamins, hormones, proteins, and nucleic acids. In that era, the textile industry was the main consumer of dyes. Access to imported natural product dyes from plants was predictable for seafaring nations, but not for landlocked nations. In parallel with natural product extraction and purification was the recognition that aniline from coal (Perkin, 1856) could be modified to generate a spectrum of colors, catalyzing the development of the German dye industry in the last half of the 19th century. Some of these synthetic dyes were found useful for histochemical staining.

Histotechnology

Morphologic diagnosis requires thin (3–5 microns), contrast-rich (requiring dyes) sections of chemically fixed (cross-linked or precipitated) tissue. Thin sections allow the passage of light through the tissue, but reduce overlapping of cells in the light path. Thus, technologies had to develop for cutting and staining of thin fixed tissue sections (reviewed in [ 14 ]). Work leading to our current technique for tissue solidification in paraffin wax was first described by Klebs in 1869. Prototypes of our current mechanical microtome for making thin (~5 micron thick) tissue sections was developed by Minot in 1885. Precursor work leading to our current technique for tissue fixation with diluted formalin was first described by Blum in 1893.

Histochemical stains developed in parallel with dye technology for the textile industry. Botanists used carmine as a stain in 1849, and subsequently Gerlack applied carmine to stain brain tissue in 1858. The current hematoxylin dye used in tissue histochemistry was originally extracted from logwood trees from Central America for the dye industry (to compete with indigo). Metallic ion mordants made oxidized hematoxylin (hematein) colorfast in textiles, and a protocol for tissue staining was published by Boehmer in 1865. Similar to the hematoxylin story, semisynthetic analine dye technology was adapted by histochemists from 1850–1900. Many of these dyes are still routinely used for recognition of tissue structure, peripheral blood cells, and microorganisms, including hematoxylin, eosin, methylene blue, Ziehl-Neelsen, Gram, van Gieson, Mallory trichrome, and Congo red [ 14 ].

The most commonly used stains for general tissue diagnosis are the hematoxylin and eosin (H&E) stains, which provide a wealth of nuclear and cytoplasmic detail not visible in an unstained section. Supplemental histochemical stains demonstrate specific structures and organisms: collagen and muscle (trichome), elastin (Verhoff-von Giessen), glycogen/mucin (periodic acid-Schiff, PAS), mucin (PAS diastase, mucicarmine, alcian blue), fungi (Gemori methenamine silver, GMS), mycobacteria (Ziehl-Neelsen, Fite), and bacteria (Gram, Warthin-Starry). Each of these stains is inexpensive ($10–$50), fast (minutes to hours), and automatable, making them extremely valuable for service diagnostic pathology use.

Light microscopy lens technology matured during the last half of the 19th century. Critical were Abbe's introductions of the apochromatic lens system to eliminate chromatic aberration (different focal lengths for different wavelengths of visible light) in 1868, a novel condenser for compound microscopes (to provide better illumination at high magnification) in 1870, and an oil immersion lens (for 10 × objective magnification with visible light) in 1878.

By 1900, maturation of tissue fixation chemistry, histochemical stain protocols, and light microscope technology had evolved into the workhorse technique for evaluation of morphologic abnormalities in tissue examination in anatomic pathology labs, and for the evaluation of morphologic features of microorganisms in microbiology labs. The scope of this chapter is limited to pathology, but it should be clear to the reader that the momentous discoveries of deep general anesthetics (Long, 1841; Morton, 1846), commercial electricity (Edison, 1882), and radiography (Roentgen, 1895) also contributed to the development of the modern medical specialties of diagnostic pathology and laboratory medicine.

Developments During the 20th Century

Humoral and cellular immunology.

The development of antisera in the 20th century for therapeutic purposes (for instance, treatment of diptheria) led to progressive understanding of the antibody, the efferent arm of the humoral immune response. Similarly, tissue transplantation experiments led to the recognition of cellular rejection [ 15 ] due to thymus-derived T-cells. Antibodies and T-cells cooperate to react to foreign (non-self) molecules, common examples being allergic responses, viral infections, and organ transplants. Antibodies were found to be made by B-cells and plasma cells, and were found to be exquisitely specific for binding to their particular antigens (ligands) either in solid phase or in solution. The analogous T-cell receptor (TCR) recognizes a ligand made up of a 15–20mer peptide presented by self MHC (HLA in human) molecules on the surface of antigen-presenting cells (macrophages, dendritic cells, activated B-cells). B- and T-cells activate and proliferate when exposed to non-self proteins, but not to self proteins, attesting to tolerance to self. When B- and T-cell self-tolerance breaks down, autoimmune diseases can result (including myasthenia gravis, Grave's disease, and lupus erythematosus). Antibodies (immunoglobulins) were found to be heterodimers of 50 kD heavy chains and 25 kD light chains, folded together so that a highly variable portion defines the antigen-binding site, and a constant portion defines the isotype (IgM, IgD, IgG, IgE, or IgA). Similarly, T-cell receptors were found to be heterodimers of immunoglobulin-like molecules with a highly variable portion for ligand binding, and a constant portion, but without different isotypes. The range of antigen-binding specificities in a normal mammal is extensive, perhaps infinite, subtracting out only those self proteins to which the animal is tolerant. The genes encoding immunoglobulins and T-cell receptors were sequenced and, surprisingly, the extensive variation of specificities was due to a unique system of gene rearrangements of polymorphic V, D, and J gene segments with random nucleotide addition at the junctions [ 16 , 17 ]. This system allows generation of literally billions of different Ig and TCR binding specificities.

Polyclonal antibodies raised in other species (goat, mouse, rabbit) against an antigen can be used to detect the antigen in diffusion gels (Ochterlony, western blot), in solution (ELISA), and in tissue sections. Use of fluorescent-tagged antibodies for frozen section immunohistochemistry was developed first [ 18 ], and immunofluorescence (IF) is still routinely used in renal pathology and dermatopathology. Peroxidase-tagged secondary antibodies and DAB chemistry were developed to generate a stable chromogen in the tissue, and this is now the primary method for detecting antigens in formalin-fixed tissue sections. Improved antibody binding specificity and industrial production required monoclonal antibodies, which required the development of mouse plasmacytomas/myelomas and cell fusion protocols [ 19 ]. The net result is that commercial antibodies are now available for antigens of both clinical and research interest, including antibodies specific enough to distinguish minimally modified variant antigens (for instance, phosphorylated versus dephosphorylated proteins).

Natural Product Chemistry and the Rise of Clinical Laboratories

Diseases due to dietary deficiencies (like scurvy) and hormonal imbalances (like diabetes mellitus) were described clinically long before they were understood pathologically. Dietary deficiency diseases prompted searches for the critical metabolic cofactors, so-called vital amines or vitamins. Xerophthalmia was linked to retinol (vitamin A) deficiency in 1917 (McCollum). Rickets was linked to calcitriol (vitamin D) deficiency in 1926. Beri-beri was linked to a deficiency of thiamine (vitamin B1) in 1926. Scurvy was linked to ascorbic acid (vitamin C) deficiency in 1927. Pellagra in the United States was linked to niacin deficiency in 1937. Pernicious anemia was linked to cobalamin (vitamin B12) deficiency in 1948. It is currently unusual to see morphologic features of these diseases in this country. Diseases due to nondietary physiologic imbalances prompted isolation of hormones. For example, hyperthyroidism and hypothyroidism were linked to thyroxine imbalances in 1915, and table salt was iodized starting in 1917. Diabetes mellitus was linked to insulin deficiency in 1921, nonhuman insulin was industrially purified and marketed soon thereafter, and recombinant human insulin was marketed in 1982.

These examples highlight the ability of 20th century chemists to fractionate, purify, synthesize, measure bioactivity, and manufacture these compounds for safe use by humans. Study of diseases due to deficiencies and excesses of single molecule function led to a mechanistic understanding of biochemistry and physiology, with resultant interconnected reaction pathways of byzantine complexity (now referred to as systems biology). Clinical demand for body fluid levels of ions (such as sodium, potassium chloride, and bicarbonate), glucose, creatinine, hormones (such as thyroxine and parathyroid hormone), albumin, enzymes (related to liver and cardiac function), and antibodies (reactive to ASO, Rh, ABO, and HLA antigens) led to the development of clinical laboratories in chemistry, endocrinology, immunopathology, and blood banking. Functional assays for coagulation cascade status were developed, as were methods for estimating blood cell concentration and differential, leading to coagulation and hematology laboratories. Serologic and cell activation assays to define HLA haplotype led to HLA laboratories screening donors and recipients in anticipation of bone marrow and solid organ transplants. Culture medium-based screening for infectious agents led to dedicated clinical microbiology laboratories, which are beginning to incorporate nucleic acid screening technologies for speciation and prediction of treatment response. The clinical laboratories now play a critical, specialized role in inpatient and outpatient management, and their high test volumes (a 700-bed hospital may perform 5 million tests per year) have catalyzed computer databases for central record-keeping of results.

Natural Product Chemistry: Nucleic Acids

The previous vignettes indicate a scientific approach to natural products of the steroid and protein types, but do not indicate how proteins are encoded, what accounts for variation in the same protein in the population, or how inherited diseases are inherited. It turns out that the instruction set for protein sequence is defined by DNA sequence. The role of nucleoproteins as a genetic substance was alluded to by Miescher in 1871, and was shown by Avery to be the pneumococcal transforming principle in 1944. The discovery of X-ray crystallography in 1912 made it possible for Franklin, Wilkins, and Gosling to study DNA crystal structure [ 20 , 21 ], and led to the description of the antiparallel double helix of DNA by Watson and Crick in 1953 [ 22 ]. This seminal event in history facilitated dissection of the instruction set for an organism, with recognition that 3-base codons specified amino acids in 1961 [ 23 ], and description of the particular codons encoding each amino acid in 1966 [ 24 ]. Demonstration of in situ hybridization in 1969 [ 25 , 26 ] made it possible to localize specific DNA or RNA sequences within the cells of interest. Recognition and purification of restriction endonucleases and DNA ligases, and the development of cloning vectors, made it possible to clone individual sequences, leading to methods for synthesis of natural products (such as recombinant human insulin in 1978 [ 27 ]). Chemical methods were developed for sequencing DNA [ 28 , 29 ], initially with radioisotope-tagged nucleotide detection in plate gels, then with fluorescent nucleotide detection in 1986 [ 30 ]. Subsequent conversion to capillary electrophoresis and computer scoring of sequence output allowed high throughput protocols which generated the human genome sequence by 2001 [ 31 , 32 ]. The development of polymerase chain reaction (PCR) [ 33 ] made it possible to quickly screen for length polymorphisms (identity testing, donor:recipient ratio after bone marrow transplant, and microsatellite instability) and sequence abnormalities (translocations, rearrangements, insertions, deletions, substitutions) in a targeted fashion. Quantitative PCR methods using fluorescent detection of amplicons made it possible to study DNA and RNA copy number, and to mimic Northern blots/oligo microarrays in estimating RNA transcript abundance for cluster analysis.

CURRENT PRACTICE OF PATHOLOGY

Diseases can be distinguished from each other based on differences at the molecular, cellular, tissue, fluid chemistry, and/or individual organism level. One hundred and fifty years of attention to the morphologic and clinical correlates of diseases has led to sets of diagnostic criteria for the recognized diseases, as well as a reproducible nomenclature for rapid description of the changes associated with newly discovered diseases. Sets of genotypic and phenotypic abnormalities in the patient are used to determine a diagnosis, which then implies a predictable natural history and can be used to optimize therapy by comparison of outcomes among similarly afflicted individuals. The disease diagnosis becomes the management variable in clinical medicine, and management of the clinical manifestations of diseases is the basis for day-to-day activities in clinics and hospitals nationwide. The pathologist is responsible for integration of the data obtained at the clinical, gross, morphologic, and molecular levels, and for issuing a clear and logical statement of diagnosis.

Clinically, diseases present to front-line physicians as patients with sets of signs and symptoms. Symptoms are the patient's complaints of perceived abnormalities. Signs are detected by examination of the patient. The clinical team, including the pathologist, will work up the patient based on the possible causes of the signs and symptoms (the differential diagnosis). Depending on the differential diagnosis, the workup typically involves history-taking, physical examination, radiographic examination, fluid tests (blood, urine, sputum, stool), and possibly tissue biopsy.

Radiographically, abnormalities in abundance, density or chemical microenvironment of tissues allows distinction from surrounding normal tissues. Traditionally, the absorption of electromagnetic waves by tissues led to summation differences in exposure of silver salt photographic film. Tomographic approaches such as CT (1972) and NMR (1973) complemented summation radiology, allowing finely detailed visualization of internal anatomy in any plane of section. In the same era, ultrasound allowed visualization of tissue with density differences, such as a developing fetus or gallbladder stones. More recently, physiology of neoplasms can be screened with positron emission tomography (PET, 1977) for decay of short half-life isotopes such as fluorodeoxyglucose. Neoplasms with high metabolism can be distinguished physiologically from adjacent low-metabolism tissues, and can be localized with respect to normal tissues by pairing PET with standard CT. The result is an astonishingly useful means of identifying and localizing new space-occupying masses, assigning a risk for malignant behavior and, if malignant, screening for metastases in distant sites. This technique is revolutionizing the preoperative decision making of clinical teams, and improves the likelihood that patients undergo resections of new mass lesions only when at risk for morbidity from malignant behavior or interference with normal function.

Pathologically, disease is diagnosed by determining whether the morphologic features match the set of diagnostic criteria previously described for each disease. Multivolume texts are devoted to the gross and microscopic diagnostic criteria used for diagnosis, prognosis, and prediction of response to therapy [ 1 , 34 , 35 ]. Pathologists diagnose disease by generating a differential diagnosis, then finding the best fit for the clinical presentation, the radiographic appearance, and the pathologic (both clinical lab and morphologic) findings. Logically, the Venn diagram of the clinical, radiologic, and pathologic differential diagnoses should overlap. Unexpected features expand the differential diagnosis and may raise the possibility of previously undescribed diseases. For example, Legionnaire's disease, human immunodeficiency virus (HIV), Hantavirus pneumonia, and severe acute respiratory syndrome (SARS) are examples of newly described diagnoses during the last 30 years. The mental construct of etiology (cause), pathogenesis (progression), natural history (clinical outcome), and response to therapy is the standard approach for pathologists thinking about a disease. A disease may have one or more etiologies (initial causes, including agents, toxins, mutagens, drugs, allergens, trauma, or genetic mutations). A disease is expected to follow a particular series of events in its development (pathogenesis), and to follow a particular clinical course (natural history). Disease can result in a temporary or lasting change in normal function, including patient death. Multiple diseases of different etiologies can affect a single organ, for example, infectious and neoplastic diseases involving the lung. Different diseases can derive from a single etiology, for example, emphysema, chronic bronchitis, and small cell lung carcinoma in long-term smokers. The same disease (for instance, emphysema of the lung) can derive from different etiologies (emphysema from α-1-antitrypsin deficiency or cigarette smoke).

Modern surgical pathology practice hinges on morphologic diagnosis, supplemented by special stains, immunohistochemical stains, cytogenetics, and clinical laboratory findings, as well as the clinical and radiographic findings. Sections that meet all of these criteria are diagnostic for the disease. If some, but not all, of the criteria are present to make a definitive diagnosis, the pathologist must either equivocate or make an alternate diagnosis. Thus, a firm grasp of the diagnostic criteria and the instincts to rapidly create and sort through the differential diagnosis must be possessed by the service pathologist.

The tissue diagnosis has to make sense, not only from the morphologic perspective, but from the clinical and radiographic vantage points as well. It is both legally risky and professionally erosive to make a clinically and pathologically impossible diagnosis. In the recent past, limited computer networking meant numerous phone calls to gather the relevant clinical and radiographic information to make an informed morphologic diagnosis. For example, certain diseases such as squamous and small cell carcinomas of the lung are extremely rare in nonsmokers. Thus, a small cell carcinoma in the lung of a nonsmoker merits screening for a nonpulmonary primary site. Fortunately for pathologists, computing and networking technologies now allow us access to preoperative clinical workups, radiographs/reports, clinical laboratory data, and prior pathology reports. All of these data protect pathologists by providing them with the relevant clinical and radiographic information, and protect patients by improving diagnostic accuracy. Just as research scientists “…ignore the literature at their peril…”, diagnostic pathologists “… ignore the presentation, past history, workup, prior biopsies, and radiographs at their peril. …”

There are limitations to morphologic diagnosis by H&E stains. First, lineage of certain classes of neoplasms (including small round blue cell tumors, clear cell neoplasms, spindle cell neoplasms, and undifferentiated malignant neoplasms) is usually clarified by immunohistochemistry, frequently by cytogenetics (when performed), and sometimes by electron microscopy. Second, there are limitations inherent in a snapshot biopsy or resection. Thus, the etiology and pathogenesis can be obscure or indeterminate, and rates of growth, invasion, or timing of metastasis cannot be inferred. Third, the morphologic changes may not be specific for the underlying molecular abnormalities, particularly the rate-limiting (therapeutic target) step in the pathogenesis of a neoplasm. For example, Ret gain of function mutations in a medullary thyroid carcinoma will require DNA level screening to determine germline involvement, familial risk, and presence or absence of a therapeutic target. Fourth, the same morphologic appearance may be identical for two different diseases, each of which would be treated differently. For example, there is no morphologic evidence by H&E stain alone to distinguish host lymphoid response to Hepatitis C viral (HCV) antigens from host lymphoid response to allo-HLA antigens in a liver allograft. This is obviously a major diagnostic challenge when the transplant was done for HCV-related cirrhosis, and the probability of recurrent HCV infection in the liver allograft is high.

Paraffin section immunohistochemistry has proven invaluable in neoplasm diagnosis for clarifying lineage, improving diagnostic accuracy, and guiding customized therapy. If neoplasms are poorly differentiated or undifferentiated, the lineage of the neoplasm may not be clear. For example, sheets of undifferentiated malignant neoplasm with prominent nucleoli could represent carcinoma, lymphoma, or melanoma. To clarify lineage, a panel of immunostains is performed for proteins that are expressed in some of the neoplasms, but not in others. Relative probabilities are then used to lend support (rule in) or exclude (rule out) particular diagnoses in the differential diagnosis of these several morphologically similar undifferentiated neoplasms. The second role is to make critical distinctions in diagnosis that cannot be accurately made by H&E alone. Examples of this would include demonstration of myoepithelial cell loss in invasive breast carcinoma but not in its mimic, sclerosing adenosis ( Figure 11.2 ), or loss of basal cells in invasive prostate carcinoma ( Figure 11.3 ). The third role of immunohistochemistry is to identify particular proteins, such as nuclear estrogen receptor (ER) ( Figure 11.4 ) or the plasma membrane HER2 proteins ( Figure 11.5 ), both of which can be targeted with inhibitors rather than generalized systemic chemotherapy. Morphology remains the gold standard in this diagnostic process, such that immunohistochemical data support or fail to support the H&E findings, not vice versa.

Sclerosing adenosis of breast . (A) H&E of sclerosing adenosis of breast. By H&E alone, the differential diagnosis includes infiltrating ductal carcinoma and sclerosing adenosis. (B) Actin immunostain of sclerosing adenosis of breast. Actin immunoreactivity around the tubules of interest supports a diagnosis of sclerosing adenosis and serves to exclude infiltrating carcinoma.

Invasive adenocarcinoma of prostate . (A) H&E of invasive adenocarcinoma of prostate. By H&E alone, the differential diagnosis includes invasive adenocarcinoma and adenosis. (B) High molecular weight cytokeratin immunostain of invasive adenocarcinoma of prostate. Loss of high molecular weight cytokeratin (34βE12) immunoreactivity around the glands of interest supports a diagnosis of invasive adenocarcinoma.

Estrogen receptor immunostain of breast carcinoma . Strong nuclear immunoreactivity for ER is noted, guiding use of ER inhibitor therapy.

HER2/c-erbB2 immunostain of breast carcinoma . Strong plasma membrane immunoreactivity for c-erbB2/HER2 is noted, guiding use of either anti-HER2 antibody or HER2 kinase inhibitor therapy.

Probability and statistics are regular considerations in immunohistochemical interpretation, since very few antigens are tissue-specific or lineage-specific. Cytokeratin is positive in carcinomas, but also in synovial and epithelioid sarcomas. This example may imply aspects of the lineage of these two sarcomas that may be helpful in our categorization of these neoplasms. Another example would be the diagnosis of small cell carcinoma in the lung of a nonsmoker. Because lung primary small cell carcinoma is extremely uncommon, in non-smokers, this diagnosis would prompt the pathologist to inquire about screening results for other, nonpulmonary, sites. Likewise, immunohistochemistry results are always put into the context of the morphologic, clinical, and radiographic findings. For example, an undifferentiated CD30(+) neoplasm of the testis supports embryonal carcinoma primary in the testis, whereas a lymph node effaced by sclerotic bands with admixed CD30(+) Reed-Sternberg cells supports nodular sclerosing Hodgkin's disease.

Demand for both diagnostic accuracy and report promptness has increased as hospitals come under increasing financial pressure to minimize length of patient stay. Hospitals now manage all but the sickest patients as outpatients. Minimally invasive approaches for the acquisition of tissue samples for diagnosis use flexible endoscopic biotomes or hollow needles that sample 1–2 mm diameter tissue specimens. Multidisciplinary conferences function almost real-time with respect to the initial biopsies. Together, these changes have forced modern pathologists to make critical diagnoses on progressively smaller biopsy specimens, sometimes bordering on the amounts seen in cytopathology aspirates, and to do this in a timely fashion. This requires a clear understanding of the limitations to development of an accurate diagnosis and a willingness on the part of the pathologist to request repeat biopsy for additional tissue when it is necessary for accurate diagnosis.

Diagnostic criteria involving electron microscopic ultrastructure found relevance for the evaluation of neoplasms described as small round blue cell tumors, spindle cell tumors, melanocytic tumors, and neuroendocrine/neuroblastic tumors, as well as delineation of ciliary ultrastructural abnormalities in primary ciliary dyskinesia. Current approaches to these neoplasms are now generally approached using paraffin section immunohistochemistry. Electron microscopy is currently used mainly for nephropathology, for evaluation of ciliary axonemes, for rare cases where immunohistochemistry is not diagnostic, and where demonstration of premelanosomes, neuroendocrine granules, or amyloid is diagnostic.

Adequate sampling of a lesion is critical to making an accurate diagnosis. Undercall diagnostic discrepancies are frequently due to sampling of a small portion of a large lesion that is unrepresentative of the most abnormal portion of the lesion. Insufficient sampling can result in an equivocal diagnosis or, worse, an inaccurate diagnosis. Empirical rules have been adopted over the decades to ensure statistically adequate sampling of masses and organs such as transurethral resections of prostate, soft tissue sarcomas, and heart allograft biopsies.

In spite of the limitations and statistical uncertainties relating to morphologic diagnosis, a wealth of information is conveyed to a service pathologist in a tried-and-true H&E section [ 36 ]. Analogous to the fact that a plain chest X-ray is the sum total of all densities in the beam path, the morphologic changes in diseased cells and tissues are the morphologic sum total of all of the disequilibria in the abnormal cells. For most neoplastic diseases, morphologic criteria are sufficient to predict the risk of invasion and metastasis (the malignant potential), the pattern of metastases, and the likely clinical outcomes. For example, the etiology and pathogenesis in small cell lung carcinoma can be inferred (cigarette smoking, with carcinogen-induced genetic mutations) and the outcome predicted (early metastasis to regional nodes and distant organs, with high probability of death within 5 years of diagnosis). New molecular data for both neoplastic and non-neoplastic diseases will most likely benefit unaffected individuals by estimating disease risk, and will most likely benefit patients by defining the molecular subset for morphologically defined diagnostic entities, thus guiding individualized therapy.

THE FUTURE OF DIAGNOSTIC PATHOLOGY

Diagnostic pathology will continue to use morphology and complementary data from protein (immunohistochemical) and nucleic acid (cytogenetics, in situ hybridization, DNA sequence, and RNA abundance) screening assays. New data will be integrated into the diagnostic process by reducing the cost and turnaround time of current technologies, and by development of new technologies, some of which are described.

Individual Identity

For transplant candidates, major histocompatability complex (MHC, HLA in human) screening is evolving from cellular assays and serology toward sequencing of the alleles of the class I and II HLA loci. Rapid sequencing of these alleles in newborn cord blood would allow databasing of the population's haplotypes, facilitating perfect matches for required bone marrow or solid organ transplants.

Rapid Cytogenetics

Current uses of in situ hybridization to screen for viruses (such as EBV), light chain restriction (in B lymphomas), and copy number variation (for instance, HER2 gene amplification) demonstrate the benefit of in situ nucleic acid hybridization assays. It is possible that interphase FISH/CISH will become rapid enough to be used in the initial diagnostic workup of certain patients, including for sarcoma-specific translocations, ploidy analysis in hydatidiform moles, and gene amplification of receptor tyrosine kinase genes.

Rapid Nucleic Acid Sequence and RNA Abundance Screening

Current uses of nucleic acid screening for bcr-abl translocation, donor:recipient ratios after bone marrow transplant, microsatellite instability, quantitative viral load (for EBV, BK, CMV, and others), and single gene mutations (for CFTR, Factor 2 , α- 1-antitrypsin ) demonstrate the benefit of nucleic acid screening in diagnosis and management. It is possible that each new neoplasm will be promptly defined as to ploidy, translocations, gene copy number differences, DNA mutations, and RNA expression cluster subset, allowing residual disease screening as well as individualized therapy.

Computer-Based Prognosis and Prediction

Current uses of morphology, immunohistochemistry, and molecular pathology demonstrate their benefit through improved diagnostic accuracy. However, diagnosis, extent of disease, and molecular subsets are currently imperfect estimators of prognosis and response to therapy. Relational databases which correlate an individual's demographic data, family history, concurrent diseases, morphologic features, immunophenotype, and molecular subset, and which integrate disease prevalence by age, sex, and ethnicity using Bayesian probabilities, should improve accuracy of prognosis and prediction of response to therapy. As risk correlates are developed, it is possible that healthy individuals will be screened and given risk estimates for development of different diseases.

Normal Ranges and Disease Risks by Ethnic Group

Current uses of normal ranges for serum chemistry assumes a similar bell-curve distribution across ages, sexes, and races. This may be true for most but not all analytes. Computer reference databases will likely generate normal ranges specific for the particular age/sex/ethnicity of individual patients. Similarly, familial risk for an inherited disease may vary by ethnic group, and this variation should be used in Bayesian calculations to define risk for unaffected at-risk family members.

Individual Metabolic Differences Relevant to Drug Metabolism

Current uses of liver and renal impairment to guide drug dosage demonstrate the benefit of using patient physiology to customize therapy. It is likely that individual differences in enzymatic metabolism of particular drugs (for instance, warfarin or tamoxifen) will be defined at the enzyme sequence level, and that gene haplotype data will be determined for new patients prior to receipt of these drugs.

Serum Biomarkers

Current uses of prostate specific antigen (PSA) to screen for prostate carcinoma and its recurrence demonstrates the benefit of serum biomarkers in common neoplasms. It is likely that high-sensitivity screening of single and clustered serum analytes will lead to improved methods for early detection and persistence of neoplasms, autoimmune diseases, and infections.

Pathologists consider each disease to have a natural, mechanical, physicochemical basis. Each disease has an etiology (initial cause), a pathogenesis (stepwise progression), and a natural history with effects on normal function (clinical outcome). Pathologists collect the data needed to answer patients' and clinicians' questions, simply phrased as “what is it?” (diagnosis), “how it going to behave?” (prognosis), and “how do I treat it?” (prediction of response to therapy). Instincts and diagnostic criteria, as well as the optical, mechanical, chemical, and computing technologies described previously, are the basis for modern service pathology. As the human genome is deciphered, and as the complex interactions of cellular biochemistry are refined, risk of disease in unaffected individuals will be calculable, disease diagnosis will be increasingly accurate and prognostic, and molecular subsets of morphologically defined disease entities will be used to guide customized therapy for individual patients. It is a great time in history to be a pathologist.

You are using an outdated browser. Upgrade your browser today or install Google Chrome Frame to better experience this site.

• Section 5 - Perspectives : Testing Travelers for Mycobacterium Tuberculosis Infection
• Section 5 - Yersiniosis

Typhoid & Paratyphoid Fever

Cdc yellow book 2024.

Author(s): Michael Hughes, Grace Appiah, Louise Francois Watkins

Infectious Agent

Transmission, epidemiology, clinical presentation, typhoid fever.

INFECTIOUS AGENT:  Salmonella enterica serotype Typhi

Latin America

Asia (greatest risk for infection is in South Asia)

TRAVELER CATEGORIES AT GREATEST RISK FOR EXPOSURE & INFECTION

PREVENTION METHODS

Follow safe food and water precautions

Typhoid fever is a vaccine-preventable disease

DIAGNOSTIC SUPPORT

Paratyphoid Fever

INFECTIOUS AGENT: Salmonella enterica serotypes Paratyphi A, B, C

Salmonella enterica serotypes Typhi, Paratyphi A, Paratyphi B, and Paratyphi C cause potentially severe and occasionally life-threatening bacteremic illnesses referred to as typhoid fever (for Typhi serotype) and paratyphoid fever (for Paratyphi serotypes), and collectively as enteric fever. Paratyphi B strains are differentiated into 2 distinct pathotypes on the basis of their ability to ferment tartrate: the first pathotype, Paratyphi B, is unable to ferment tartrate and is associated with paratyphoid fever; the second pathotype, Paratyphi B var. L(+) tartrate(+), ferments tartrate and is associated with gastroenteritis typical of nontyphoidal salmonellosis. For more details on nontyphoidal salmonellosis, see the Sec. 5, Part 1, Ch. 19, Nontyphoidal Salmonellosis .

Humans are the only source of the bacteria that cause enteric fever; no animal or environmental reservoirs have been identified. Typhoid and paratyphoid fever are acquired through consumption of water or food contaminated by feces of an acutely infected or convalescent person, or a person with chronic, asymptomatic carriage. Risk for infection is high in low- and middle-income countries with endemic disease and poor access to safe food and water, and poor sanitation. Sexual contact, particularly among men who have sex with men, has been documented as a rare route of transmission.

An estimated 11–21 million cases of typhoid fever and 5 million cases of paratyphoid fever occur worldwide each year, causing an estimated 135,000–230,000 deaths. In the United States during 2016–2018, ≈400 culture-confirmed cases of typhoid fever and 50–100 cases of paratyphoid fever caused by Paratyphi A were reported each year; paratyphoid fever caused by Paratyphi B and Paratyphi C is rarely reported. Approximately 85% of typhoid fever and 92% of paratyphoid fever cases in the United States occur among international travelers; most are in travelers returning from South Asia, primarily Bangladesh, India, and Pakistan. Other high-risk regions for infection include Africa, Latin America, and Southeast Asia; lower-risk regions include East Asia and the Caribbean.

Travelers visiting friends and relatives are at increased risk because they might be less careful with food and water while abroad than other travelers and might not seek pretravel health consultation or typhoid vaccination (see Sec. 9, Ch. 9, Visiting Friends & Relatives: VFR Travel ). Although the risk of acquiring illness increases with the duration of stay, travelers have acquired typhoid fever even during visits of <1 week to countries where the disease is highly endemic (e.g., Bangladesh, India, Pakistan).

The incubation period of both typhoid and paratyphoid infections is 6–30 days. The onset of illness is insidious, with gradually increasing fatigue and a fever that increases daily from low-grade to 102°F–104°F (38°C–40°C) by the third or fourth day of illness. Fever is commonly lowest in the morning, peaking in the late afternoon or evening. Anorexia, headache, and malaise are nearly universal, and abdominal pain, constipation, or diarrhea are common. Diarrhea and vomiting are more common in children than in adults. People also can have dry cough, fatigue, myalgias, and sore throat. Hepatosplenomegaly often can be detected. A transient, maculopapular rash of rose-colored spots can occasionally be seen on the trunk.

The clinical presentation is often confused with malaria. Suspect enteric fever in a person with a history of travel to an endemic area who is not responding to antimalarial medication. Untreated, the disease can last for a month, and reported case-fatality ratios are 10%–30%. By comparison, the case-fatality ratio in patients treated early is usually <1%. Serious complications of typhoid fever occur in 10%–15% of hospitalized patients, generally after 2–3 weeks of illness, and include life-threatening gastrointestinal hemorrhage, intestinal perforation, and encephalopathy. Paratyphoid fever appears to have a lower case-fatality ratio than typhoid fever; however, severe cases do occur.

Typhoid and paratyphoid fever are nationally notifiable diseases in the United States. Clinicians should report cases to their state or local health department. Identification of a domestically acquired case should prompt a public health investigation to prevent other cases.

Blood Culture

Patients with typhoid or paratyphoid fever typically have bacteremia; blood culture is therefore the preferred method of diagnosis. A single culture is positive in only ≈50% of cases, however. Multiple blood cultures increase the sensitivity and might be required to make the diagnosis. Depending on the blood culture system used, cultures might need to be held and observed for up to 7 days before reporting a negative result. Although bone marrow culture is more invasive (and therefore less commonly performed), it increases the sensitivity to ≈80% of cases and is relatively unaffected by previous or concurrent antibiotic use. Stool culture is not usually positive during the first week of illness and has less diagnostic sensitivity than blood culture. Urine culture has a lower diagnostic yield than stool culture.

Rapid Diagnostic Tests

Globally, several commercial rapid diagnostic tests for typhoid fever are available, but their sensitivity and specificity are not optimal. The Widal test measures elevated antibody titers; it is unreliable but widely used in developing countries because of its low cost. Serologic tests do not distinguish acute from past infection or vaccination and lack specificity; thus, blood culture remains the preferred method to diagnose acute infections.

Clinical Diagnosis

Poor sensitivity and specificity of rapid antibody tests and the time it takes to obtain a positive culture mean that the initial diagnosis must often be made clinically. Typhoid and paratyphoid fever are clinically indistinguishable. The combination of risk factors for infection and gradual onset of fever that increases in severity over several days should raise suspicion of enteric fever.

Antibiotic therapy shortens the clinical course of enteric fever and reduces the risk for death. Treatment decisions are complicated by high rates of resistance to many antimicrobial agents, and antimicrobial treatment should be guided by susceptibility testing. A careful travel history can inform empiric treatment choices while awaiting culture results.

Multidrug-Resistant Infection

Established resistance to older antibiotics (e.g., ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole) has led to these agents being recommended only as alternative antibiotics for infections with known susceptibility. Multidrug-resistant (MDR) Typhi with resistance to all 3 of these antibiotics has been present for decades. Regional estimates for MDR Typhi range from 9% in South Asia (2015–2018) to 35%–59% in parts of Africa (2010–2014).

Fluoroquinolones (e.g., ciprofloxacin) are still considered the treatment of choice for fluoroquinolone-susceptible infections in adults. Most Typhi and Paratyphi A infections in the United States are fluoroquinolone-nonsusceptible, however, and most (>90%) have occurred among travelers returning from South Asia. Fluoroquinolone-nonsusceptible infections have been associated with treatment failure or delayed clinical response. Therefore, azithromycin and ceftriaxone, antibiotics with historically low rates of resistance globally, are increasingly being used as empiric treatment for enteric fever.

Extensively Drug-Resistant Infection

In 2017, among all Typhi and Paratyphi A isolates tested by CDC’s National Antimicrobial Resistance Monitoring System (NARMS), <1% were resistant to azithromycin or to ceftriaxone, based on resistance criteria for Typhi. Resistance to both agents is emerging, however. In 2016, an outbreak of extensively drug-resistant (XDR) typhoid fever began in Sindh Province, Pakistan. These XDR Salmonella Typhi isolates are typically resistant to ampicillin, ceftriaxone, chloramphenicol, ciprofloxacin, and trimethoprim-sulfamethoxazole, but susceptible to azithromycin and carbapenem antibiotics.

The first US cases of XDR typhoid fever associated with travel to Pakistan were diagnosed in 2018, and by early 2021 >70 XDR infections had been documented among residents of the United States, including 9 cases among patients who did not travel internationally in the 30 days before illness began. Ceftriaxone resistance also has been identified in Typhi isolates from US travelers returning from Iraq. Additionally, resistance to azithromycin has been identified among Typhi and Paratyphi strains isolated from patients in Bangladesh, Cambodia, India, Nepal, Pakistan, Saudi Arabia, and the United States.

Empiric treatment should be guided by the patient’s travel history. For patients with suspected typhoid fever who traveled to Iraq or Pakistan, or who did not travel internationally before their illness began, empirically treat uncomplicated illness with azithromycin, and treat complicated illness with a carbapenem. Ceftriaxone remains an appropriate empiric treatment option for travelers returning from most other countries. Once culture results are available, use susceptibility information to guide treatment. Case reports have suggested that patients with XDR Typhi infection who do not improve on a carbapenem alone might benefit from the addition of a second antibiotic (e.g., azithromycin). Updated information about antimicrobial resistance among isolates from US patients with enteric fever in the United States can be found at the NARMS website .

Cases Unresponsive to Treatment

Patients treated with antimicrobial agents can continue to have fever for 3–5 days, but the maximum temperature generally decreases each day. Patients sometimes feel worse during the first few days after commencing antibiotic treatment. If fever in a person with typhoid or paratyphoid infection does not subside within 5 days of initiating antibiotic therapy, however, consider treatment with alternative antibiotics or begin looking for a persistent focus of infection (e.g., an abscess, or an infection in a bone, joint, or other extraintestinal site).

Relapse, Reinfection & Chronic Carriage

Relapse, reinfection, and chronic carriage also can occur. Relapse occurs in ≤10% of patients 1–3 weeks after clinical recovery, requiring further antibiotic treatment. An estimated 1%–4% of treated patients become asymptomatic chronic carriers (defined as people who excrete the organism in stool for ≥12 months); a prolonged antibiotic course is usually required to eradicate the organism.

Food & Water Precautions

Safe food and water precautions and frequent handwashing, especially before meals, are important in preventing both typhoid and paratyphoid fever (see Sec. 2, Ch. 8, Food & Water Precautions ). Although recommended by the Advisory Committee on Immunization Practices (ACIP), typhoid vaccines are not 100% effective, and a large bacterial inoculum can overwhelm vaccine-induced immunity. Therefore, vaccinated travelers should follow recommended food and water precautions to prevent enteric fever and other infections. No vaccines are available for paratyphoid fever; thus, food and water precautions are the only prevention methods.

Indications

The ACIP recommends typhoid vaccine for travelers going to areas where risk for exposure to Typhi is recognized. Destination-specific vaccine recommendations are available at the CDC Travelers’ Health website. Two typhoid vaccines are licensed for use in the United States: Vi capsular polysaccharide vaccine (ViCPS) (Typhim Vi, manufactured by Sanofi Pasteur) for intramuscular use; and live attenuated vaccine (Vivotif, manufactured from the Ty21a strain of serotype Typhi by PaxVax) for oral use. Both vaccines are unconjugated, which means the polysaccharide antigens are not paired with a protein to elicit a strong response from the immune system. Because these vaccines protect 50%–80% of recipients, remind travelers that typhoid immunization is not 100% effective, and take the opportunity to reinforce safe food and water precautions. Neither vaccine is licensed to prevent paratyphoid fever, although limited data from efficacy trials suggest that the Ty21a vaccine might provide some cross-protection against Paratyphi B.

Newer, protein conjugated Vi vaccines have greater efficacy in children <2 years old and protect people for longer than Vi unconjugated polysaccharide vaccines. Three typhoid Vi conjugate vaccines (TCV) have been licensed in India: Peda Typh (manufactured by Biomed); Typbar-TCV (manufactured by Bharat Biotech); and Zyvac TCV (manufactured by Zydus Cadila). Typbar-TCV also is licensed in Cambodia, Nepal, and Nigeria. Although none of these vaccines are licensed or available in the United States, Tybar-TCV received prequalification from the World Health Organization in 2018. The vaccine is approved for use in people ≥6 months old. In a human challenge study, Typbar-TCV had ≈87% protective efficacy. Interim analysis from a large field study in Nepal has shown Typbar-TCV effectiveness of 81.6% in children after 15 months of follow-up.

Administration

For information on dosage, administration, and revaccination for the 2 typhoid vaccines licensed in the United States, see Table 5-07 . The time required for primary vaccination differs, as do the lower age limits for each.

Table 5-07 Typhoid fever vaccines

Abbreviations: IM, intramuscular; NA, not applicable.

1 Vaccine must be kept refrigerated at 35°F–46°F (2°C–8°C).

2 Capsules should be taken with cool liquid, no warmer than 98.6°F (37°C)

VI Capsular Polysaccharide Vaccine

Primary vaccination with ViCPS consists of one 0.5-mL (25-μg) dose administered intramuscularly ≥2 weeks before travel. The vaccine is approved for use in people ≥2 years old. A dose is recommended every 2 years for those who remain at risk.

Live Attenuated Ty21A Vaccine

Primary vaccination with Ty21a vaccine consists of 4 capsules, 1 taken every other day. The capsules should be kept refrigerated (not frozen), and all 4 doses must be taken to achieve maximum efficacy. Each capsule should be swallowed whole (not chewed) and taken with cool liquid no warmer than 98.6°F (37°C), approximately 1 hour before a meal and ≥2 hours after a previous meal. The manufacturer recommends avoiding alcohol consumption 1 hour before and 2 hours after administration, because alcohol can disintegrate the enteric coating.

Travelers should complete the Ty21a vaccine regimen ≥1 week before potential exposure. The approach for addressing a missed oral vaccine dose or taking a dose late is undefined. Some suggest that minor deviations in the dosing schedule (e.g., taking a dose 1 day late) might not alter vaccine efficacy; no studies have shown the effect of such deviations, however. If travelers do not complete 4 doses as directed, they might not achieve an optimal immune response. The vaccine is approved for use in people ≥6 years old. A booster dose is recommended every 5 years for those who remain at risk.

Adverse Reactions

Adverse reactions most often associated with ViCPS vaccine include headache, injection-site reactions, fever, and general discomfort. Adverse reactions to Ty21a vaccine are rare and mainly consist of abdominal discomfort, diarrhea, fever, headache, nausea, vomiting, and rash. Report adverse reactions to the Vaccine Adverse Event Reporting System at the website or by calling 800-822-7967.

Precautions & Contraindications

Neither the ViCPS nor the Ty21a vaccine should be given to people with an acute febrile illness; in addition, Ty21a is not recommended for use in people with acute gastroenteritis. Live vaccines, including Ty21a vaccine, should not be given to pregnant or immunocompromised people, including those with HIV. No information is available on the safety of the inactivated vaccine (ViCPS) in pregnancy; consider ViCPS for pregnant people when the benefits of vaccination outweigh potential risks (e.g., when the likelihood of exposure to Typhi is high).

The intramuscular vaccine (ViCPS) presents a theoretically safer alternative than the live, oral vaccine (Ty21a) for immunocompromised travelers. The Ty21a vaccine can be administered to household contacts of immunocompromised people; although vaccine organisms can be shed transiently in the stool of vaccine recipients, secondary transmission of vaccine organisms has not been documented. The only contraindication to vaccination with ViCPS vaccine is a history of severe local or systemic reactions after a previous dose.

Theoretical concerns have been raised about the immunogenicity of Ty21a vaccine in people concurrently receiving antimicrobial agents, live vaccines, or immune globulin. The growth of the live Ty21a strain is inhibited in vitro by various antimicrobial agents. The manufacturer advises that vaccination with the Ty21a vaccine should be delayed for >72 hours after the administration of any antimicrobial agent, and antibiotics should not be given to a patient ≤72 hours after the last dose of the Ty21a vaccine.

Ty21a vaccine can be administered simultaneously or at any interval before or after live virus vaccines (e.g., measles-mumps-rubella, oral polio, or yellow fever vaccines). Available data do not suggest that simultaneous administration of live virus vaccines decreases the immunogenicity of the Ty21a vaccine. If typhoid vaccination is warranted, it should not be delayed because of administration of viral vaccines. No data are available on coadministration of the Ty21a vaccine and the oral cholera vaccine (lyophilized CVD 103-HgR [Vaxchora]); taking the first Ty21a vaccine dose ≥8 hours after oral cholera vaccine might decrease potential interference between the vaccines. Simultaneous administration of the Ty21a vaccine and immune globulin does not appear to pose a problem.

CDC website: Typhoid fever and paratyphoid fever

The following authors contributed to the previous version of this chapter: Grace D. Appiah, Michael J. Hughes, Kevin Chatham-Stephens

Bibliography

Browne AJ, Kashef Hamadani BH, Kumaran EAP, Rao P, Longbottom J, Harris E, et al. Drug-resistant enteric fever worldwide, 1990 to 2018: a systematic review and meta-analysis. BMC Med. 2020;18(1):1.

Crump JA. Progress in typhoid fever epidemiology. Clin Infect Dis. 2019;68(Suppl 1):S4–9.

Crump JA, Sjölund-Karlsson M, Gordon MA, Parry CM. Epidemiology, clinical presentation, laboratory diagnosis, antimicrobial resistance, and antimicrobial management of invasive Salmonella infections. Clin Microbiol Rev. 2015;28(4):90137.

Date KA, Bentsi-Enchill A, Marks F, Fox K. Typhoid fever vaccination strategies. Vaccine. 2015;33:C55–61.

Date KA, Newton AE, Medalla F, Blackstock A, Richardson L, McCullough A, et al. Changing patterns in enteric fever incidence and increasing antibiotic resistance of enteric fever isolates in the United States, 2008–2012. Clin Infect Dis. 2016;63(3):322–9.

Effa EE, Lassi ZS, Critchley JA, Garner P, Sinclair D, Olliaro P, Bhutta ZA. Fluoroquinolones for treating uncomplicated typhoid and paratyphoid fever (enteric fever). Cochrane Database Syst Rev. 2011(10):CD004530.

François Watkins LK, Winstead A, Appiah GD, Friedman CR, Medalla F, Hughes MJ, et al. Update on extensively drug-resistant Salmonella serotype Typhi infections among travelers to or from Pakistan and report of ceftriaxone-resistant Salmonella serotype Typhi infections among travelers to Iraq—United States, 2018–2019. MMWR Morb Mortal Wkly Rep. 2020;69(20):618–22.

Jackson BR, Iqbal S, Mahon B. Updated recommendations for the use of typhoid vaccine—Advisory Committee on Immunization Practices, United States, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(11):305–8.

Klemm EJ, Shakoor S, Page AJ, Qamar FN, Judge K, Saeed DK, et al. Emergence of an extensively drug-resistant Salmonella enterica serovar Typhi clone harboring a promiscuous plasmid encoding resistance to fluoroquinolones and third-generation cephalosporins. mBio. 2018;9(1):e00105–18.

Lynch MF, Blanton EM, Bulens S, Polyak C, Vojdani J, Stevenson J, et al. Typhoid fever in the United States, 1999–2006. JAMA. 2009;302(8):859–65.

McAteer J, Derado G, Hughes M, Bhatnagar A, Medalla F, Chatham-Stephens K, et al. Typhoid fever in the US pediatric population, 1999–2015: opportunities for improvement. Clin Infect Dis. 2021; (73)11:e4581–9.

Stanaway JD, Reiner RC, Blacker BF, Goldberg EM, Khalil IA, Troeger CE, et al. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Infect Dis. 2019;19(4):369–81.

Syed KA, Saluja T, Cho H, Hsiao A, Shaikh H, Wartel TA, et al. Review on the recent advances on typhoid vaccine development and challenges ahead. Clin Infect Dis. 202029;71(Suppl_2):S141–50.

File Formats Help:

• Adobe PDF file
• Microsoft PowerPoint file
• Microsoft Word file
• Microsoft Excel file
• Audio/Video file
• Apple Quicktime file
• RealPlayer file
• Zip Archive file

Exit Notification / Disclaimer Policy

• The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
• Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
• You will be subject to the destination website's privacy policy when you follow the link.
• CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.

Division of Extension

Biosecurity Practices Presentations Aim to Educate Livestock Owners to Help Mitigate Disease Spread

• Share on Facebook
• Share on X (Twitter)
• Share via Email

Staff from the Wisconsin Department of Agriculture, Trade and Consumer Protection (DATCP) and the University of Wisconsin-Madison Division of Extension produced a series of three educational videos on how to protect livestock from disease-causing microorganisms.

The videos offer biosecurity measures livestock owners can take to reduce the risk of introducing and spreading diseases found in Wisconsin.

“No one is more vested in the success of your livestock operation than you are. Your farm’s biosecurity plan depends on you,” said DATCP Assistant State Veterinarian Dr. Elisabeth Patton. “Successful biosecurity plans are dependent on consistent and thorough management steps that you and everyone on your operation practice every single day to reduce the risk to your animals and your herd.”

The three educational videos are hosted on the DATCP YouTube channel .

Basic Biosecurity Practices For Livestock Operations

The first video focuses on basic biosecurity practices for livestock operations.

Biosecurity Practices For Livestock At Fairs, Shows, And Exhibitions

The Second video outlines practices for biosecurity at fairs, shows, and exhibitions.

Biosecurity During a Disease Outbreak

The third video provides an overview of biosecurity during disease response.

The videos offer instructions for practicing four critical steps to help stop the spread of disease including exclusion, separation, cleaning, and disinfecting. Tips for biocontainment and risk assessment are also provided. 

The videos are appropriate for all age levels, from youth who are planning to show animals at a fair for the first time, to longtime producers. Regardless of experience level caring for livestock, these videos demonstrate how to protect animals and prevent the spread of diseases.

“Biosecurity means keeping animals healthy by protecting them from diseases. Anytime we bring animals together from different farms, there is a risk of sharing germs,” UW-Extension Senior Outreach Specialist Sandy Stuttgen said. “However, there are steps you can take to reduce the risk of introducing and spreading diseases while attending shows and steps to take to not bring diseases home to your farm.”

The videos were created with the expertise of UW-Madison Division of Extension educators and outreach specialists including Sandy Stuttgen, Heather Schlesser, and Carolyn Ihde, DATCP veterinarians Dr. Elisabeth Patton and Dr. Becky Johnson, and DATCP emergency management specialist Kurt Grajkowski.

DATCP and UW-Madison Division of Extension encourage all to share the videos widely with friends, colleagues, coworkers, and family who could benefit from the information.

Funding for this work was provided by United States Department of Agriculture’s Animal and Plant Health Inspection Services Veterinary Services (USDA-APHIS-VS) through a cooperative agreement with DATCP.

Connect with the Extension Dairy Team

Extension dairy news, subscribe to our dairy newsletter.

Extension Dairy Articles

We teach, learn, lead and serve, connecting people with the University of Wisconsin, and engaging with them in transforming lives and communities.

Explore Extension »

Connect with your County Extension Office »

Find an Extension employee in our staff directory »

Get the latest news and updates on Extension's work around the state

Feedback, questions or accessibility issues: [email protected] | © 2024 The Board of Regents of the University of Wisconsin System Privacy Policy | Non-Discrimination Policy & How to File a Complaint | Disability Accommodation Requests

An EEO/AA employer, University of Wisconsin-Madison Division of Extension provides equal opportunities in employment and programming, including Title VI, Title IX, the Americans with Disabilities Act (ADA) and Section 504 of the Rehabilitation Act requirements.

April 2024 ZOHU Call

Per- and Polyfluoroalkyl Substances: Understanding Exposure and Adverse Health Outcomes in People and their Pets

Responding to Avian Influenza A H5N1 Detection on a Hospital Property in Maine- An Interdisciplinary Approach

Multistate outbreaks of salmonellosis linked to contact with backyard poultry — United States, 2015–2022

Date: Wednesday, April 3, 2024

Time:  2:00-3:00 pm (Eastern Time)

Web-on-Demand: A captioned video recording will be posted within 30 days after the call.

See and hear the presentations and ask questions online.

Please use the link below and enter the passcode: zohu@apr3

https://cdc.zoomgov.com/j/1616182064?pwd=TUhqYkc4cXNmOWR6NDFwODBLQndYQT09

Listen only by phone

US: +1 669 254 5252 US (San Jose) or +1 646 828 7666 US (New York) or +1 646 964 1167 US (US Spanish Line) or +1 551 285 1373 US (New Jersey) or +1 669 216 1590 US (San Jose) or +1 415 449 4000 US (US Spanish Line) Passcode: 382451033

International numbers available: https://cdc.zoomgov.com/u/acHYLNkQLe

Get Free CE for ZOHU Calls

Starting January 1, 2024, please visit CDC Train to receive continuing education (CE) for all new webcast and web-on-demand courses.

Registration Code: ZOHUwebcast Webcast: WC4565(SC)-040324 Origination Date: April 3, 2024 Expiration Date: May 6, 2024

Web-on-Demand: WD4565(SC)-040324 Origination Date: May 7, 2024 Expiration Date: May 7, 2026

Presentations

Heather Brake MS DVM DACVPM Communications Director National Center for Environmental Health Agency for Toxic Substances and Disease Registry Centers for Disease Control and Prevention Graduate Student, Michigan State [email protected]

Responding to Avian Influenza A H5N1 Detection on a Hospital Property in Maine- An Interdisciplinary Approach Anna Krueger, MS Epidemiologist; Influenza Surveillance Coordinator Maine Center for Disease Control and Prevention (Maine CDC) [email protected]

Multistate outbreaks of salmonellosis linked to contact with backyard poultry — United States, 2015–2022 G. Sean Stapleton, DVM, MPH Veterinary Epidemiologist Division of Foodborne, Waterborne, and Environmental Diseases Outbreak Response and Prevention Branch/Enteric Zoonoses Activity Centers for Disease Control and Prevention [email protected]

• Current per- and polyfluoroalkyl substance (PFAS) research points to a growing threat in animals
• Responding to avian influenza A H5N1 detection on a hospital property in Maine—An interdisciplinary approach
• Backyard Poultry

Overall series objectives

• Identify an implication for human, animal, and environmental health.
• Identify a One Health approach strategy for prevention of public health threats.
• Identify a One Health approach strategy for detection of public health threats.
• Identify a One Health approach strategy for responding to public health threats.
• List two ways to improve collaborative practice across the public healthcare team.

Disclosures

In compliance with continuing education requirements, all presenters must disclose any financial or other associations with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters as well as any use of unlabeled product(s) or product(s) under investigational use.

CDC, our planners, presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters.

The planning committee reviewed content to ensure there is no bias.

The presentations will not include any discussion of the unlabeled use of a product or a product under investigational use.

CDC did not accept commercial support for this activity.

To receive a monthly update highlighting our recent work to prevent infectious disease, enter your email address:

Exit Notification / Disclaimer Policy

• The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
• Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
• You will be subject to the destination website's privacy policy when you follow the link.
• CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.

• Case Report
• Open access
• Published: 28 March 2024

Unusual presentation and delayed diagnosis of cardiac angiosarcoma

• Salman Zaheer 1 ,
• Alice L. Zhou 1 ,
• John M. Gross 2 &
• Ahmet Kilic 1  

Journal of Cardiothoracic Surgery volume  19 , Article number:  161 ( 2024 ) Cite this article

11 Accesses

Metrics details

Primary cardiac angiosarcomas are very rare and present aggressively with high rates of metastasis. Given the poor prognosis, particularly once disease has spread, early diagnosis and multidisciplinary treatment is essential.

Case presentation

We present the case of a 46-year-old male who presented with chest pain, intermittent fevers, and dyspnea. Workup with computed tomography scan and transesophageal echocardiography demonstrated a right atrial pseudoaneurysm. Given the concern for rupture, the patient was taken to the operating room, where resection of the pseudoaneurysm and repair using a bovine pericardial patch was performed. Histopathology report initially demonstrated perivascular lymphocyte infiltrate. Six weeks later, the patient represented with chest pain and new word finding difficulty. Workup revealed multiple solid lung, pericardial, brain, and bone nodules. Eventual biopsy of a cardiophrenic nodule demonstrated angiosarcoma, and rereview of the original pathology slides confirmed the diagnosis of primary cardiac angiosarcoma.

Conclusions

Primary cardiac angiosarcomas are often misdiagnosed given the rarity of these tumors, but early diagnosis and initiation of treatment is essential. The unique presentation of our case demonstrates that clinical suspicion for cardiac angiosarcoma should be maintained for spontaneous pseudoaneurysm originating from the right atrium.

Peer Review reports

Primary cardiac angiosarcomas are very aggressive tumors that often present after metastatic spread. Given the aggressive nature of the disease, early diagnosis is essential. We describe the case of a patient with primary cardiac angiosarcoma who initially presented with a right atrial pseudoaneurysm.

We present a case of 46-year-old male with no pertinent past medical history who presented to the emergency department with ongoing chest pain for 9 days associated with intermittent fevers and shortness of breath. On examination, the patient had a heart rate of 88 beats per minute and blood pressure of 143/72 mmHg. There were no audible murmurs or rubs on auscultation. He endorsed ongoing chest pain and shortness of breath.

The patient underwent contrast computed tomography (CT) angiography pulmonary embolism with pulmonary arterial phase timing that showed no evidence of pulmonary embolism, but demonstrated a moderate sized pericardial effusion with high density concerning for hemopericardium, along with an outpouching on the right atrial wall with a narrow neck concerning for a pseudoaneurysm (Fig.  1 ). Further workup, including lab work and an electrocardiogram, were unremarkable. Transesophageal echocardiogram (TEE) redemonstrated the pericardial effusion and right atrial pseudoaneurysm (Fig.  2 ).

Computed tomography angiogram of the chest. Computed tomography angiogram showing a right atrial pseudoaneurysm. Neck of the pseudoaneurysm is shown by the green arrow. Attenuation of the pericardial fluid was 28.4 Hounsfield units

Transesophageal echocardiogram of pseudoaneurysm. Pseudoaneurysm with pericardial effusion redemonstrated on transesophageal echocardiogram arising from right atrium

The case was discussed at the multidisciplinary cardiac conference and the decision was made to take the patient to the operating room given his ongoing symptoms as well as concern for hemopericardium and rupture of pseudoaneurysm into the pericardial space. Cardiac magnetic resonance imaging (MRI) and positron emission tomography (PET) CT were not performed given time-sensitive nature of the case and the desire for tissue diagnosis. The operation was performed via median sternotomy with cardiopulmonary bypass. A pericardial effusion and dense pericardial adhesions were found intraoperatively. After meticulous lysis of adhesions, central cannulation was performed, and the aorta and right atrium were cannulated. Right atrial pseudoaneurysm was identified (Fig.  3 ) and excised with the surrounding atrial wall. The defect in the atrial wall was closed using a bovine pericardial patch. Full exploration of the chest revealed no other lesions. The resected specimen was sent for pathology to try to establish tissue diagnosis and the patient was closed. The patient’s post-operative course was unremarkable, and he was discharged home on post operative day 4. Operative cultures showed no growth. Pericardial fluid cytopathology demonstrated abundant mixed inflammation with eosinophils, reactive mesothelial cells, histiocytes, and lymphocytes, with no malignant neoplasm identified. Tissue histopathology demonstrated granulation tissue, perivascular lymphocyte infiltrate, dense fibrous tissue, focal calcification, and organizing fibrin thrombus, but no evidence of malignancy.

Intra-operative photos of pseudoaneurysm. Pseudoaneurysm demonstrated by green arrow. A Blue arrow indicates pseudoaneurysm. B Green arrow indicates bovine pericardial patch used to repair defect in atrial wall after pseudoaneurysm resection

Six weeks postoperatively, the patient presented to emergency department with chest pain, new word finding difficulty, clumsiness, gait instability, and intermittent low-grade fevers. A CT chest scan showed multiple halo-like solid lung, pericardial, and bone nodules (Fig.  4 A, B ). The CT head scan showed 1–1.5 cm left anterior thalamic and left temporal lobe hemorrhagic lesions. Magnetic resonance imaging of the brain demonstrated multiple enhancing lesions in the left temporal lobe, left anterior thalamus, and right parietal lobe (Fig.  4 C). Together, the findings were suspicious for hemorrhagic metastasis, invasive fungal infection (such as invasive aspergillosis), or septic emboli. Given the concern for metastatic process, a biopsy of a lung nodule was performed and showed focal organizing exudative and fibrotic pneumonia negative for carcinoma. A lumbar puncture was also performed and showed no malignant neoplasm. Given the repeated surgical specimens that were negative for malignancy, an extensive infectious and rheumatologic workup was pursued. He was discharged with outpatient infectious disease follow-up, as the most likely diagnosis on the differential was thought to be invasive fungal infection and cultures would take several weeks to result.

Imaging findings on representation. A Computed tomography (CT) of chest showing multiple lung nodules (green arrows). B CT of chest showing nodular appearance of pericardial effusion and outpouching of the right atrium. C Head magnetic resonance imaging (MRI) demonstrating peripherally enhancing lesions (red arrow)

He represented one week later with returned right-sided chest pain, intermittent headaches, and abdominal pain. Repeat CT scan demonstrated increased number of pulmonary and pericardial nodules. Given the patient’s diagnostic dilemma and ongoing symptoms, a cardiophrenic nodule was biopsied with image guidance. Pathology demonstrated atypical cells, anaplasia, and poorly-formed vascular lumina, suggestive of angiosarcoma (Fig.  5 ).

Pathology findings demonstrating angiosarcoma. A low power magnification (× 12.5) hematoxylin and eosin staining of pseudoaneurysm reveals fibrin and organizing hematoma with a variably cellular fibrous cyst wall. B High power magnification (× 400) of pseudoaneurysm reveals scattered enlarged pleomorphic tumor cells with rare atypical mitoses in the background of abundant reactive granulation tissue. C Cardiophrenic nodule (× 400) shows similar atypical cells with unequivocal anaplasia and poorly-formed vascular lumina. D Cardiophrenic nodule (× 400) shows malignant endothelial cells with endothelial hobnailing into the vascular lumen

The patient’s tissue biopsy from his initial right atrial pseudoaneurysm resection was retrospectively reviewed and similar atypical cells were noted in the background of granulation tissue and organizing thrombus (Fig.  5 ). A diagnosis of primary cardiac angiosarcoma was made. The patient is currently undergoing chemotherapy with weekly paclitaxel for metastatic cardiac angiosarcoma.

Discussion and conclusions

Primary tumors of the heart are very rare and are identified in only 1 in 500 cardiac surgical cases. Of these, malignant tumors make up only 25%, the majority (95%) of which are cardiac sarcomas [ 1 ]. Angiosarcomas are the most common histologic subtype of cardiac sarcomas (30%) and are very aggressive in nature with high rates of metastasis [ 2 ].

Cardiac angiosarcomas more frequently present in males (2–3:1 male:female ratio) and most commonly arise from the right atrium [ 3 ]. Patients often present with nonspecific symptoms such as chest pain, dyspnea, weight loss, and fatigue [ 1 ]. Later in the disease course, patients may present with more specific symptoms, such as pericardial effusion, due to local infiltration into the myocardium and neighboring structures. Over half of patients present with metastatic disease, with spread to the lungs or pleura being most common [ 3 ]. Imaging can aid in the diagnosis of cardiac angiosarcomas. CT scan often shows a large multilobular mass that comprises the majority of the right atrium [ 4 ]. Transthoracic echocardiography (TTE) often shows a large echogenic mass with poorly defined borders and can be used to understand the size and location of the mass, understand its relation to other structures, and determine if cardiac function is affected [ 5 ]. Magnetic resonance imaging (MRI) can be used to differentiate between thrombus and tumor [ 6 ]. Histopathologically, angiosarcomas are difficult to diagnose due to the cellular heterogeneity. Common tumor markers include CD34, CD31, and factor VIII [ 1 ].

Due to the aggressive nature of this cancer, early diagnosis is essential. Our case represented a diagnostic challenge and initially presented on imaging as a right atrial pseudoaneurysm with a narrow neck, as opposed to a large multilobular mass with broad-based attachment typically described for cardiac angiosarcoma [ 4 , 5 ]. Diagnosis was further delayed by the challenging histologic presentation in the context of low clinical suspicion, with malignant cells being obscured by extensive fibrin, granulation tissue, and organizing thrombus. Given these difficulties, diagnosis was not made until after distant metastatic spread and a cardiophrenic metastatic lesion was biopsied.

Given the rarity of this tumor and high mortality rate, there is no standardized approach to treatment. Without surgical resection, average survival is about 4 months [ 1 ]. The mainstay of treatment involves complete surgical resection, with a median post-operative survival of about 14 months [ 1 , 3 ]. However, achieving complete resection with negative margins is often difficult given the diagnostic delay and proximity to vascular structures and propensity for distant microscopic spread at time of diagnosis. Chemotherapy and radiation are often used in the treatment either as neoadjuvant or adjuvant therapy, but the exact role of these modalities remains unknown [ 7 , 8 ]. Overall, a multidisciplinary approach involving local resection, systemic chemotherapy, and radiation therapy seems to be the most favorable strategy.

Primary cardiac angiosarcomas are often misdiagnosed given the rarity of these tumors. Cardiac angiosarcoma presenting initially on imaging as either a right atrial pseudoaneurysm or a right coronary artery aneurysm has only been reported in a handful of case reports [ 9 , 10 , 11 , 12 , 13 , 14 ]. The unique presentation of this case demonstrates that clinical suspicion for cardiac angiosarcoma should be maintained for spontaneous pseudoaneurysm originating from the right atrium. With an aggressive disease course, early diagnosis is vital and allows for multidisciplinary care with medical and radiation oncology to offer patients the best chances of survival.

Availability of data and materials

Not applicable.

Abbreviations

Computed tomography

Magnetic resonance imaging

Positron emission tomography

Transesophageal echocardiogram

Transthoracic echocardiography

Patel SD, Peterson A, Bartczak A, et al. Primary cardiac angiosarcoma—a review. Med Sci Monit. 2014;20:103–9. https://doi.org/10.12659/MSM.889875 .

Article   CAS   PubMed   PubMed Central   Google Scholar  

Ferguson PC. Surgical considerations for management of distal extremity soft tissue sarcomas. Curr Opin Oncol. 2005;17(4):366–9. https://doi.org/10.1097/01.cco.0000166651.38417.c8 .

Article   PubMed   Google Scholar  

Look Hong NJ, Pandalai PK, Hornick JL, et al. Cardiac angiosarcoma management and outcomes: 20-year single-institution experience. Ann Surg Oncol. 2012;19(8):2707–15. https://doi.org/10.1245/s10434-012-2334-2 .

Kassop D, Donovan MS, Cheezum MK, et al. Cardiac masses on cardiac CT: a review. Curr Cardiovasc Imaging Rep. 2014;7(8):9281. https://doi.org/10.1007/s12410-014-9281-1 .

Article   PubMed   PubMed Central   Google Scholar  

Luo L, Zhao W, Wang Y, Liu K. Cardiac angiosarcoma: a case report and review of the literature. Echocardiography. 2021;38(12):2083–90. https://doi.org/10.1111/echo.15221 .

Riles E, Gupta S, Wang DD, Tobin K. Primary cardiac angiosarcoma: a diagnostic challenge in a young man with recurrent pericardial effusions. Exp Clin Cardiol. 2012;17(1):39–42.

PubMed   PubMed Central   Google Scholar  

Penel N, Bui BN, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study. JCO. 2008;26(32):5269–74. https://doi.org/10.1200/JCO.2008.17.3146 .

Article   CAS   Google Scholar  

Blackmon SH, Reardon MJ. Surgical treatment of primary cardiac sarcomas. Tex Heart Inst J. 2009;36(5):451–2.

Sawamura T, Takiya H, Yamada T, Sugimoto H, Kawai H. A case of cardiac angiosarcoma with a pseudoaneurysm formed in the right coronary artery. Kyobu Geka. 1994;47(7):565–8.

CAS   PubMed   Google Scholar  

Serra V, Moura L, Almería C, Pérez de Isla L, Zamorano J. Right atrial rupture. Rev Port Cardiol. 2004;23(5):731–6.

PubMed   Google Scholar  

Berry MF, Williams M, Welsby I, Lin S. Cardiac angiosarcoma presenting with right coronary artery pseudoaneurysm. J Cardiothorac Vasc Anesth. 2010;24(4):633–5. https://doi.org/10.1053/j.jvca.2009.04.002 .

Chaturvedi A, Vummidi D, Shuman WP, Dubinsky TJ, Maki JH. Cardiac angiosarcoma: an unusual cause of coronary artery pseudoaneurysm. J Thorac Imaging. 2012;27(1):W8. https://doi.org/10.1097/RTI.0b013e3182078187 .

Kimura S, Yonekura R, Umesue M. Angiosarcoma mimicking an infected pseudoaneurysm after graft replacement. Ann Thorac Surg. 2015;100(3):1114. https://doi.org/10.1016/j.athoracsur.2015.05.084 .

Murthy JSN, Gorantla R, Periyasamy T, et al. Right atrial angiosarcoma presenting as giant pseudoaneurysm with impending rupture. IHJ Cardiovasc Case Rep. 2017;1(3):165–8. https://doi.org/10.1016/j.ihjccr.2016.09.002 .

Article   Google Scholar  

Download references

Acknowledgements

Author information, authors and affiliations.

Division of Cardiac Surgery, Department of Surgery, The Johns Hopkins Hospital, Baltimore, MD, USA

Salman Zaheer, Alice L. Zhou & Ahmet Kilic

Bone and Soft Tissue Pathology, The Johns Hopkins Hospital, 1800 Orleans Street, Zayed Tower Suite 7107, Baltimore, MD, 21287, USA

John M. Gross

You can also search for this author in PubMed   Google Scholar

Contributions

SZ: Concept/design, drafting article, critical revision of article, approval of article. AZ: Drafting article, critical revision of article, approval of article. JG: pathological examination of the tumor sample, drafting of the article, critical revision of the article, and approval of the article. AK: Concept/design, critical revision of article, approval of article. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Salman Zaheer or Ahmet Kilic .

Ethics declarations

Ethics approval and consent to participate, consent for publication.

Consent was obtained from the patient for the publication of this report.

Competing interests

Additional information, publisher's note.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ . The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/ ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Cite this article.

Zaheer, S., Zhou, A.L., Gross, J.M. et al. Unusual presentation and delayed diagnosis of cardiac angiosarcoma. J Cardiothorac Surg 19 , 161 (2024). https://doi.org/10.1186/s13019-024-02555-8

Download citation

Received : 21 April 2023

Accepted : 30 January 2024

Published : 28 March 2024

DOI : https://doi.org/10.1186/s13019-024-02555-8

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

• Cardiac tumor
• Pseudoaneurysm
• Angiosarcoma
• Tumor resection
• Case report

Journal of Cardiothoracic Surgery

ISSN: 1749-8090

• General enquiries: [email protected]